A new self-expanding aortic stent valve with annular fixation: in vitro haemodynamic assessment

Vergnat, Mathieu; Hénaine, Roland; Kalējs, Mārtiņš; Bommeli, Sandra; Ferrari, Enrico; Obadia, Jean François; Segesser, Ludwig Karl von

doi:10.1016/j.ejcts.2009.01.052

Cited by 11 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Symetis transapical TAVR system is a self-positioning bioprosthesis composed of a noncoronary leaflet of surgical quality porcine tissue valve sewn into a self-expanding nitinol stent that is covered with a PET-skirt (Fig. 1) [4]. The transapical delivery system is designed for quick, two-step, single-operator deployment.…”

Section: The Valvementioning

confidence: 99%

Symetis Acurate Transapical Aortic Valve: the initial experience with a second generation of transcatheter aortic valve replacement device

et al. 2014

View full text Add to dashboard Cite

This brief clinical communication reports the first Polish experience with the second generation of TAVR device - the Symetis Acurate Transapical Aortic Valve. While it lacks large patient population and longer follow-up, it reveals that TAVR procedure can be performed safely, with minimal X-ray exposure time and contrast given and successfully - with almost nonexistent PVL and no cerebrovascular incidents or heart rhythm disturbances. Heart Team approach is vital, and transapical access should not be treated inferiorly, but rather as an equally appealing TAVR option.

show abstract

Section: The Valvementioning

confidence: 99%

Symetis Acurate Transapical Aortic Valve: the initial experience with a second generation of transcatheter aortic valve replacement device

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Fig. 3, [14,15]). A porcine valve made of three noncoronary leaflets (already CE marked) is fixed within the lower part of the Nitinol® stent.…”

Section: Symetis Acurate ™ Valvementioning

confidence: 99%

Current developments in transcatheter aortic valve implantation techniques

Thielmann

Konorza

Erbel

et al. 2011

Herz

View full text Add to dashboard Cite

Transcatheter aortic valve implantation (TAVI) has become a viable treatment option in high-risk patients with symptomatic aortic stenosis. The widespread uses of TAVI procedures in recent years and the steadily growing evolution of numerous new catheter-based devices have led to a remarkable shift in the treatment of this patients group towards TAVI procedures. Several developments have now overcome most of the initial problems with the early devices and have been quickly implemented in clinical routine. Nevertheless, several current TAVI systems have shown a number of limitations and disadvantages relating to valve design, the occurrence of paravalvular leakages, valve positioning and deployment, the occurrence of thromboembolic events during the procedure, as well as vascular or conduction complications. As a result, all current efforts in further development focus primarily on the following issues: (1) the further miniaturization of catheter devices and sheaths not only to facilitate transarterial but also transapical access; (2) the development of a broad variety of valve sizes to cover all aortic annulus sizes; (3) the development of retrievable, repositionable and removable systems; (4) the development or modification of stent design to prevent or reduce paravalvular leakages; (5) the implementation of modern imaging and navigation tools; (6) and finally, the initial development of prophylactic devices to prevent thromboembolic events. The present article provides a review of current developments in the field of TAVI.

show abstract

“…The stentvalve evolution will also provide new stent-valves for transapical and transfemoral applications, such as the Symetis stent-valve (Symetis SA, Lausanne, Switzerland) (fig. 11), and the Ventor Embracer™ stent-valve (Medtronic, Minneapolis, MN) for an exclusive transapical use, or the JenaClip™ stent-valve (JenaValve Technology, Munich, Germany) for both transapical and transfemoral applications [57,58]. These new stented valves will bring innovations such as a greater variety of sizes, expected durability (due to the employed biological tissues and their treatment), simplicity in use (in particular for the valve positioning and implantation, and for the delivery system), and some interesting characteristics such as the self-orientation (the stent-valve leaflets will fit within the native aortic valve leaflets) and the self expandability without need for rapid cardiac pacing.…”

Section: Figure 11mentioning

confidence: 99%

Transcatheter aortic valve implantation (TAVI): state of the art techniques and future perspectives

Ferrari¹,

Segesser²

2010

Swiss Med Wkly

View full text Add to dashboard Cite

Transcatheter aortic valve therapies are the newest established techniques for the treatment of high risk patients affected by severe symptomatic aortic valve stenosis. The transapical approach requires a left anterolateral mini-thoracotomy, whereas the transfemoral method requires an adequate peripheral vascular access and can be performed fully percutaneously. Alternatively, the trans-subclavian access has been recently proposed as a third promising approach. Depending on the technique, the fine stent-valve positioning can be performed with or without contrast injections. The transapical echo-guided stent-valve implantation without angiography (the Lausanne technique) relies entirely on transoesophageal echocardiogramme imaging for the fine stent-valve positioning and it has been proved that this technique prevents the onset of postoperative contrast-related acute kidney failure. Recent published reports have shown good hospital outcomes and short-term results after transcatheter aortic valve implantation, but there are no proven advantages in using the transfemoral or the transapical technique. In particular, the transapical series have a higher mean logistic Euroscore of 27-35%, a procedural success rate above 95% and a mean 30-day mortality between 7.5 and 17.5%, whereas the transfemoral results show a lower logistic Euroscore of 23-25.5%, a procedural success rate above 90% and a 30-day mortality of 7-10.8%. Nevertheless, further clinical trials and long-term results are mandatory to confirm this positive trend. Future perspectives in transcatheter aortic valve therapies would be the development of intravascular devices for the ablation of the diseased valve leaflets and the launch of new stent-valves with improved haemodynamic, different sizes and smaller delivery systems.

show abstract

A new self-expanding aortic stent valve with annular fixation: in vitro haemodynamic assessment

Abstract: Implantation of this new self-expanding stent valve with annular fixation has little impact on haemodynamics and has the potential for working heart implantation in vivo. Flow reduction (rapid pacing) is not necessary.

Cited by 11 publications

References 26 publications

Symetis Acurate Transapical Aortic Valve: the initial experience with a second generation of transcatheter aortic valve replacement device

Symetis Acurate Transapical Aortic Valve: the initial experience with a second generation of transcatheter aortic valve replacement device

Current developments in transcatheter aortic valve implantation techniques

Transcatheter aortic valve implantation (TAVI): state of the art techniques and future perspectives

Contact Info

Product

Resources

About